Bayer seeks wider use for eye drug Eylea in Europe

FRANKFURT Thu Nov 7, 2013 6:15am EST

FRANKFURT Nov 7 (Reuters) - German drugmaker Bayer said it filed for marketing approval in Europe for the use of eye drug Eylea as a treatment of diabetic macular oedema.

Bayer has said it expects Eylea, also known as VEGF Trap-Eye, to generate more than 1 billion euros ($1.35 billion) in peak annual sales.

The injection, which Bayer is co-developing with Regeneron , is already approved for other eye diseases.

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.